Branded Legacy,
Inc. Strengthens Position in BioTech Industry with
Letter of Intent to Purchase Sycamore
BioPharma, LLC
The Company will
secure over 2 Million in assets as well as personnel
necessary for clinical trials in upcoming acquisition
Melbourne, FL --
February 29, 2024 -- InvestorsHub NewsWire
-- Branded
Legacy (OTC.PK:
BLEG), Inc., a
leading BioTech holdings company, announced today
the
signed letter of intent
to purchase Sycamore BioPharma, LLC, an established developer of
plant based pharmaceuticals. The strategic move aligns with Branded
Legacy's commitment to expanding its portfolio in the biotech
sector and further solidifies its position as a key player in the
industry.
Sycamore BioPharma has garnered a reputation as a
prolific product developer, offering a meticulously curated line of
wellness solutions ranging from gummies to compression sleeves and
pain-relieving topical creams. They
currently possess over 2 million in assets and over $500,000 in
high quality ready to sell inventory. With a
commitment to quality, authenticity, and a passion for natural
ingredients, Sycamore BioPharma has become a trusted name in the
industry.
"Branded Legacy is excited to welcome Sycamore
BioPharma into our family of companies," said David Oswald, CEO at
Branded Legacy, Inc. "This strategic acquisition will not only
complement our existing portfolio but also reinforces our
commitment to providing innovative solutions for wellness and
health. Sycamore BioPharma's expertise in botanical extracts,
sustainable plant-based products, and natural Active Pharmaceutical
Ingredients perfectly aligns with our vision for the future of
bio-tech."
The collaboration between Branded Legacy and
Sycamore BioPharma is poised to create synergies across various
aspects of the business. Branded Legacy's web properties, brand
management, and marketing teams will work in tandem with Sycamore
BioPharma to maximize the reach and impact of their innovative
wellness solutions. This integration will enable a seamless
exchange of ideas, expertise, and resources to enhance customer
experiences and elevate both brands in the
market.
In addition Branded Legacy will add
another PHD holding scientist, Dr. Mark Hamann, to its
roster.
This will not only bolster efforts in
developing novel pharmaceuticals, but will also streamline the FDA
approval process, especially with regards to clinical
trials.
"Sycamore BioPharma has crafted a unique and
high-quality product line, and we see immense potential in
amplifying its reach through our branding, marketing, and sales
channels," said Doug Holladay, CMO at Branded Legacy, Inc. "Our
dedicated teams will work closely to integrate Sycamore BioPharma's
offerings into our comprehensive strategy, ensuring that these
exceptional wellness solutions reach a broader
audience."
The acquisition will provide Sycamore BioPharma
with access to Branded Legacy's extensive network, enabling the
company to tap into new markets and demographics. The combined
resources and expertise of both companies will enhance Sycamore
BioPharma's ability to connect with consumers, build brand loyalty,
and drive sales growth.
Sycamore BioPharma brings state-of-the-art
extraction equipment to the table, further bolstering Branded
Legacy's already robust extraction capabilities. This combined
technological prowess will fuel advancements in product
development, ensuring the delivery of superior,
research-backed remedies that
set new standards in the biotech industry. "We are thrilled to
welcome Sycamore BioPharma into the Branded Legacy family. This
strategic acquisition will greatly enhance our existing
technological infrastructure The
addition of their high volume Critical CO2 extraction capabilities
to our existing CO2 capacity is a crucial step in securing a major
Kavalactone extraction and refinement contract. In turn we will
employ our recently acquired topical and cosmetic packaging
equipment as a huge cost saving measure to Sycamore BioPharm's
operations. Together, our combined capabilities propel us to the
forefront of innovation, ensuring the delivery of high-quality,
scientifically-backed solutions that set new standards in the
biotech industry." Said Joseph Holladay, Branded Legacy
COO.
Branded Legacy, Inc. looks forward to the strategic
collaboration with Sycamore BioPharma, aiming to drive innovation,
improve customer experiences, and shape the future of the biotech
industry. With a shared dedication to quality, authenticity, and a
passion for wellness, the partnership between Branded Legacy and
Sycamore BioPharma is poised to reshape the landscape of natural
products processing and sustainable plant-based
solutions.
This acquisition comes at a great time
as Branded Legacy has recently signed several large white label
manufacturing deals, ensuring throughput and creating a clear path
to profitability.
For more information about Sycamore BioPharma, LLC,
please visit: https://sycamorebp.com/
For media inquiries, please
contact:
Investor Relations & Media
Contact
Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email: info@brandedlegacy.com
Website: https://brandedlegacy.com/
About Branded
Legacy, Inc.:
Branded Legacy, Inc. (OTC: BLEG) is a
diversified holdings company focused on the biotech sector. With a
commitment to excellence and innovation, Branded Legacy specializes
in the development and marketing of cutting-edge products and
services. The company's diverse portfolio includes ventures in
biotechnology, digital solutions, and wellness products, all aimed
at enhancing the quality of life for its customers. Branded
Legacy's strategic approach to growth involves identifying and
integrating promising businesses and technologies that align with
its mission to deliver sustainable, high-quality products and
services.
Safe Harbor
Statement on Forward-Looking Language:
This release includes
forward-looking statements, which are based on certain assumptions
and reflect management's current expectations. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. Some of these factors include
general global economic conditions; general industry and market
conditions and growth rates; uncertainty as to whether our
strategies and business plans will yield the expected benefits;
increasing competition; availability and cost of capital; the
ability to identify and develop and achieve commercial success; the
level of expenditures necessary to maintain and improve the quality
of services; changes in the economy; changes in laws and
regulations, includes codes and standards, intellectual property
rights, and tax matters; or other matters not anticipated; our
ability to secure and maintain strategic relationships and
distribution agreements. Dilution, if any, would be for the
purposes of management taking stock in lieu of cash salary. The
company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise. Additionally, this press
release that is not statements of historical fact may be considered
to be forward-looking statements. Written words such as "may,"
"will," "expect," "believe," "anticipate," "estimate," "intends,"
"goal," "objective," "seek," "attempt," or variations of these or
similar words, identify forward-looking statements. By their
nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the near future.
